Unfortunately, while there are targeted therapies available for ER+ and HER2+ breast cancer, no targeted therapy is available for TNBC or IBC (Inflammatory Breast Cancer), which have a worse outcome than other subtypes. Here, ESR1 is linked to breast cancer.